Enterprise-wide Disclosures (Details) (USD $)	3 Months Ended	12 Months Ended				12 Months Ended									1 Months Ended	12 Months Ended				12 Months Ended
	Dec. 31, 2012	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	Apr. 29, 2009	Dec. 31, 2012 Hospira [Member]	Dec. 31, 2011 Hospira [Member]	Dec. 31, 2010 Hospira [Member]	Dec. 31, 2012 C J [Member]	Dec. 31, 2011 C J [Member]	Dec. 31, 2010 C J [Member]	Dec. 31, 2012 Summit [Member]	Dec. 31, 2011 Summit [Member]	Dec. 31, 2010 Summit [Member]	Feb. 28, 2013 C I R M [Member]	Dec. 31, 2012 C I R M [Member]	Dec. 31, 2011 C I R M [Member]	Dec. 31, 2010 C I R M [Member]	Apr. 30, 2009 C I R M [Member]	Dec. 31, 2012 QTDP [Member]	Dec. 31, 2011 QTDP [Member]	Dec. 31, 2010 QTDP [Member]	Dec. 31, 2012 OCS [Member]	Dec. 31, 2011 OCS [Member]	Dec. 31, 2010 OCS [Member]	Dec. 31, 2012 Others [Member]	Dec. 31, 2011 Others [Member]	Dec. 31, 2010 Others [Member]	Dec. 31, 2012 N I H [Member]	Dec. 31, 2012 Cell Cure Neurosciences, Ltd. [Member]	Dec. 31, 2012 LifeMap Sciences, Ltd. [Member]
Geographic Area [Abstract]
Domestic		$ 2,529,669	$ 3,059,810	$ 3,311,211
Asia		1,385,658	1,374,349	396,807
Total revenues		3,915,327	4,434,159	3,708,018
Revenue, Major Customer [Line Items]
Number of major customers	3	3
Number of major grants	3	3
Award granted from research project	392,664	392,664			4,721,706														4,721,706										335,900
Payment received from research project	261,777	392,665	1,570,663												392,664	392,665	1,570,663												45,645		1,222,516
Grants revenue		2,222,458	2,767,181	2,336,325												1,047,106	1,570,663												47,507	1,109,699	18,145
Advertising revenue																															373,798
Revenues of royalty and commission fees																															$ 379,098
Percentage of total revenues (in hundredths)						11.00%	14.20%	22.70%	2.90%	3.50%	6.80%	3.70%	3.30%	3.90%		26.70%	35.40%	42.50%		0.00%	0.00%	19.80%	26.00%	23.00%	0.00%	29.70%	20.60%	4.30%